.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
UBS
Julphar
Queensland Health
Colorcon
Healthtrust
Fish and Richardson
US Army
Medtronic
Novartis

Generated: December 15, 2017

DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE CONS, and when can generic versions of GLAXOSMITHKLINE CONS drugs launch?

GLAXOSMITHKLINE CONS has eleven approved drugs.

There are twelve US patents protecting GLAXOSMITHKLINE CONS drugs.

There are three hundred and twenty-six patent family members on GLAXOSMITHKLINE CONS drugs in forty-eight countries and eighteen supplementary protection certificates in eleven countries.

Summary for Glaxosmithkline Cons

International Patents:326
US Patents:12
Tradenames:10
Ingredients:10
NDAs:11
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxosmithkline ConsEXCEDRIN (MIGRAINE)acetaminophen; aspirin; caffeineTABLET;ORAL020802-001Jan 14, 1998OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxosmithkline ConsPREVACID 24 HRlansoprazoleCAPSULE, DELAYED REL PELLETS;ORAL022327-001May 18, 2009OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline ConsCOMMITnicotine polacrilexTROCHE/LOZENGE;ORAL021330-002Oct 31, 2002OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline ConsTAVIST-1clemastine fumarateTABLET;ORAL020925-001Aug 21, 1992OTCYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxosmithkline ConsNICORETTEnicotine polacrilexTROCHE/LOZENGE;ORAL022360-001May 18, 2009OTCYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxosmithkline ConsFLONASE SENSIMIST ALLERGY RELIEFfluticasone furoateSPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline ConsLAMISILterbinafineGEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
Glaxosmithkline ConsCOMMITnicotine polacrilexTROCHE/LOZENGE;ORAL021330-001Oct 31, 2002► Subscribe► Subscribe
Glaxosmithkline ConsALLIorlistatCAPSULE;ORAL021887-001Feb 7, 2007► Subscribe► Subscribe
Glaxosmithkline ConsLAMISILterbinafine hydrochlorideSOLUTION;TOPICAL020749-001Oct 17, 1997► Subscribe► Subscribe
Glaxosmithkline ConsCOMMITnicotine polacrilexTROCHE/LOZENGE;ORAL021330-002Oct 31, 2002► Subscribe► Subscribe
Glaxosmithkline ConsLAMISILterbinafine hydrochlorideSOLUTION;TOPICAL020749-001Oct 17, 1997► Subscribe► Subscribe
Glaxosmithkline ConsLAMISILterbinafineGEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
Glaxosmithkline ConsLAMISILterbinafineGEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
Glaxosmithkline ConsEXCEDRIN (MIGRAINE)acetaminophen; aspirin; caffeineTABLET;ORAL020802-001Jan 14, 1998► Subscribe► Subscribe
Glaxosmithkline ConsLAMISILterbinafineGEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXOSMITHKLINE CONS drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine polacrilexGum2 mgNICORETTE1/22/2013
nicotine polacrilexGum4 mgNICORETTE1/22/2013
orlistatCapsules60 mgALLI9/8/2010

Non-Orange Book Patents for Glaxosmithkline Cons

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,858,593 Anti-inflammatory androstane derivative compositions► Subscribe
7,629,335Anti-inflammatory androstane derivative► Subscribe
7,498,32117.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents► Subscribe
6,537,983 Anti-inflammatory androstane derivatives► Subscribe
6,878,698 Anti-inflammatory androstane derivatives► Subscribe
7,531,528Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,125,985Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
6,777,399 Anti-inflammatory androstane derivative compositions► Subscribe
7,798,368Fluid dispensing device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxosmithkline Cons Drugs

Country Document Number Estimated Expiration
Yugoslavia49423► Subscribe
Taiwan533082► Subscribe
Germany60311831► Subscribe
World Intellectual Property Organization (WIPO)2005044354► Subscribe
Germany60131750► Subscribe
Czech Republic304043► Subscribe
Denmark1868731► Subscribe
Slovenia1775305► Subscribe
Portugal994714► Subscribe
Portugal921796► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
14/008Ireland► SubscribePRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C011/2008Ireland► SubscribeSPC011/2008: 20081105, EXPIRES: 20230110
C/GB98/044United Kingdom► SubscribePRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
12/2008Austria► SubscribePRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1305329/01Switzerland► SubscribePRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
2008000029Germany► SubscribePRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
UBS
US Army
Cantor Fitzgerald
Colorcon
Fuji
Johnson and Johnson
Accenture
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot